Rates of resistance and heteroresistance to newer β-lactam/β-lactamase inhibitors for carbapenem-resistant Enterobacterales.
Christina K LinAlex PageSarah LohsenAli A HaiderJesse WaggonerGillian SmithAhmed BabikerLindsey B GottliebJessica R Howard-AndersonSarah W SatolaPublished in: JAC-antimicrobial resistance (2024)
Twenty-four percent of CRE isolates tested were either resistant or heteroresistant (HR) to newer BL/BLIs, with an overall decrease of ∼10% susceptibility over 6 years. While newer BL/BLIs remain active against most CRE, these findings support the need for ongoing antibiotic stewardship and a better understanding of the clinical implications of HR in CRE.